<DOC>
	<DOCNO>NCT00383097</DOCNO>
	<brief_summary>The purpose study obtain blood ( 90 ml 18-teaspoonfuls one two occasion ) make LMP1- LMP2-cytotoxic T-lymphocytes grow laboratory way able attack LMP1- LMP2-positive cell laboratory . If successful grow cell feel would helpful donor , would give cell back donor . This trial patient type lymph gland cancer call Hodgkin non-Hodgkin lymphoma , chronic active Epstein Barr virus ( EBV ) infection , come back go away treatment , include best treatment know . This research study use special immune system cell call LMP1- LMP2-specific cytotoxic T lymphocytes ( LMP1- LMP2-CTLs ) , new experimental therapy . As chronic active EBV infection , patient Hodgkin non-Hodgkin lymphoma show evidence infection virus cause infectious mononucleosis ( EBV ) time diagnosis Lymphoma . EBV find cancer cell half patient lymphoma , suggest may play role cause lymphoma . The cancer cell infect EBV able hide body 's immune system escape destruction . We want see special white blood cell , call T cell , train kill EBV infected cell survive patient 's blood affect EBV-positive cell . In present study try find improve treatment grow T cell recognize two protein express lymphoma cell call LMP1 LMP2 . These special T cell call LMP1- LMP2-specific cytotoxic CTLs .</brief_summary>
	<brief_title>Lmp1 Lmp2 Specific CTLs Following Cd45 Antibody Relapsed Ebv-Positive Hodgkin 's Or Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Infusions CD45 MAbs A fix dose CD45 MAbs use determine previous ongoing study stem cell transplant recipient use 40 , 400ug/kg 6 8 hrs daily x 4 give daily intravenous infusion complete 48-72 hour prior CTL infusion . Patients premedicated prior CD45 infusion monitor per SOP CD45 MAbs infusion . Day 1 Day 4 : YTH 24/54 400ug/kg 6 8 hr ; Day 5 : Rest ; Day 6 , 7 8 : CTL Infusion ( provide CD45 Mab level &lt; 100 ng/ml ) Preparation Patient : Oxygen suction equipment must available room . Emergency drug ( Benadryl , Epinephrine , solucortef solumedrol ) appropriate dos must preordered physician prior initiation infusion dose available . A code card contain appropriate dos medicine accord patient 's weight also available . Continuous telemetric monitoring pulse oximeter EKG begin prior 6 hour antibody infusion take place . Baseline vital sign take record monitored per SOP antibody infusion . MAbs Infusion : The antibody aliquot infuse arrive treatment area hand-carried attending physician appoint designate . The antibody aliquot dilute minimal amount normal saline . The resulting solution stable 24 hour . The antibody solution administer syringe pump incremental dos , 0.2-0.8 mg first hour 10 mg/hr thereafter , maximum infusion time 8 hr . A registered nurse physician must readily available Antibody toxicity : Volume Overload : This particular importance small recipient monitor carefully . Inflammatory mediator release damage circulate white cell allergic reaction : Fever , chill , rigor , pruritis , urticaria , nausea , vomit , throat tightness dyspnea may occur . These reaction usually respond slow stop infusion and/or parenteral administration diphenhydramine , hydrocortisone , meperidine anti-emetics . Administration O2 , epinephrine , bronchodilator IPPB may necessary . Adverse effect CD45 MAbs CTL Our experience date show rapid clearance CD45 MAbs plasma , level undetectable 24-48hrs infusion . However , MAb level measure CTL infusion free plasma CD45 MAbs present CTL infusion defer 24 hour CTL Infusion : Dose Levels CTLs : The follow dose level evaluate : Each patient receive 1 injection , accord follow dosing schedule : Dose level I : 2 x 10e7 cells/m2 ; Dose level II : 1 x 10e8 cells/m2 ; Dose level III : 3 x 10e8 cells/m2 ; Dose level IV : 1 x 10e9 cells/m2 . Patients pre-medicated Benadryl 1mg/kg IV ( max 50mg ) Tylenol 10mg/kg po ( max 650mg ) . Cell Administration : LMP1- LMP2-specific T cell give intravenous injection 1-10 minute either peripheral central line .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Diagnosis EBVpositive Hodgkin 's disease ( HD ) , nonHodgkin 's lymphoma ( NHL ; histological subtypes except Burkitt 's lymphoma ) , EBV ( associate ) T/NKLPD , chronic active EBV infection ( CAEBV ) second subsequent relapse include autologous syngeneic stem cell transplant ( first relapse active disease immunosuppressive chemotherapy contraindicate ) . CAEBV define ) illness great 3 month duration ( EBVrelated illness symptom include fever , persistent hepatitis , extensive lymphadenopathy , hepatosplenomegaly ) ; ii ) increase amount EBVDNA peripheral blood ( equal great 400 genome copy per ug DNA ) abnormal high level EBV antibody ( VCA IgG equal great 1:5120 EA IgG equal great 1:640 ; iii ) evidence previous immunological abnormality recent infection might explain observed condition . Patients life expectancy great 6 week . Patients Karnofsky score ( age ≥16 ) great 50 Lansky score ( age &lt; 16 ) great 50 No severe intercurrent infection . HIV negative donor ( autologous donor , patient must HIV negative ) Patient , parent/guardian able give inform consent . Patients bilirubin less than3 x normal , AST le 5 x normal , Hgb great 8.0 Patients creatinine less 2 x normal age Patients investigational therapy include T cell therapy one month prior entry study . Female patient reproductive capacity must negative pregnancy test . Women childbearing potential must pregnant must effective birth control . The male partner use condom . Note : Patients would exclude protocol strictly laboratory abnormality include investigator¡¦s discretion approval CAGT Protocol Review Committee FDA reviewer . Patient , parent/guardian unable unwilling give inform consent Pregnant woman Patients Karnofsky score &lt; 50 Patients severe intercurrent infection Patients life expectancy &lt; 6 week Patients bilirubin great 3x normal . AST great 5x normal Hgb le 8.0 g/dl Patients creatinine great 2x normal age Due unknown effect therapy fetus , pregnant woman exclude research . The male partner use condom . Note : Patients would exclude protocol strictly laboratory abnormality include investigator 's discretion approval CCGT Protocol Review Committee FDA reviewer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>CTLs</keyword>
	<keyword>LMP1</keyword>
	<keyword>LMP2</keyword>
	<keyword>CYTOTOXIC T-LYMPHOCYTES</keyword>
	<keyword>CD45</keyword>
	<keyword>ANTIBODY</keyword>
	<keyword>EBV-POSITIVE HODGKIN 'S</keyword>
	<keyword>NON-HODGKIN 'S LYMPHOMA</keyword>
</DOC>